OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
PathoQuest will apply its experience in viral safety testing and quality control of biologics for mitigating the risk of adventitious agent contamination in biopharmaceutical manufacturing.
February 02, 2021
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
Having a clear and detailed understanding of exactly what a biomolecule entails is essential for therapeutics development.
Outsourcing partners can provide a multitude of advantages in the development of drug delivery solutions, including those designed for targeted patient populations.
Collaboration between equipment suppliers and users is leading to innovation and optimization in biopharmaceutical manufacturing.